Investment in Biomarkers for Drug Development
Alzheimer’s disease (AD) is one of the most prevalent dementia in the world. According to the Alzheimer’s disease facts and figures, it is estimated that in every 33 seconds, a new case of AD occurs, a very high prevalence of almost 35 million patients around the world. Consequently, the development of clinical diagnostics and therapeutics for AD and other neurodegenerative conditions is becoming very important. In about 10% to 15% of cases, clinical diagnosis of AD is inaccurate. To overcome this hurdle, certain biomarkers are used, which improve the accuracy of the diagnosis. Biomarkers are neurochemical indicators that are used to access the risk or prevalence of a disease. Biomarkers also find application in drug development for AD. Several biomarkers are used for the detection of various stages of Alzheimer’s disease. Examples include beta-amyloid and tau levels in the cerebrospinal fluid and brain changes that are detectable by imaging. Recently, researchers at the Sanford Burnham Prebys Medical Discovery Institute (SBP) identified a new biomarker, which is a peptide (DAG) that may lead to early detection of AD. The peptide identifies a protein that increases in the brain blood vessels of mice and human Alzheimer patients. Thus, investments in the development of biomarkers for drug development and early detection of AD are acting as the major driver and fuelling the growth of the Alzheimer's disease diagnostics & therapeutics market globally.
Other factors that help in the growth of the market are increasing pipeline drug development, increasing incidence and prevalence of Alzheimer's disease, increasing sophisticated diagnostics for early detection and precise drug development, and emerging novel diagnostic techniques.
Early Diagnosis of the Indication is challenging
Alzheimer’s disease (AD) is becoming a major public health threat, due to the increasing number of the affected individuals. According to the Translational Research & Clinical Intervention, there are 5.3 million Americans and 35 million people worldwide that are suffering from Alzheimer disease. As Alzheimer disease is spreading in the world, new therapies are urgently needed for the diagnosis and treatment of the disease. Early diagnosis of AD is challenging, and the early symptoms of the AD are commonly overlooked, because the symptoms are mild and the anatomical changes in the brain and central nervous symptoms are not necessarily visible through medical imaging. This limitation has serious implications, as late-stage diagnosis leaves the patients with only symptomatic relief options through medications, thereby limiting the overall benefit the patient could have received through early medication and diagnosis. Consequently, the limitations in early-stage diagnosis of AD is constraining the growth of the AD diagnostics and therapeutics market globally.
Other factors restraining the market are decrease in the market due to failures of late-stage drugs, lack of surrogate markers for drug discovery and drug development, and insufficient research funding and lengthy uncertain processes.
The United States is the global leader in AD Intervention and Management
According to the Alzheimer’s Association, more than 5 million Americans are living with AD, as of 2017. The United States is considered as the global leader in Alzheimer’s disease intervention and management. The United States has a large pool of biopharmaceutical companies, which cumulatively have a total of 85 drugs in various stages in the pipeline for combating Alzheimer’s disease. The United States holds a major share of around 83% of the total revenue in North America.
Key Developments in the Market
- January 2018: Johnson & Johnson Innovation LLC and Janssen Pharmaceuticals Inc. (JPI) established an exclusive research collaboration with the University of Pennsylvania’s Gene Therapy Program.
- October 2017: Eisai and Biogen Inc. expanded their existing agreement to develop and commercialize investigation AD treatments jointly.
- August 2017: St. Vincent’s Institute of Medical Research collaborated with Johnson & Johnson Innovation for developing and commercializing small molecule modulators of microglial function and inflammation, with the aim of reducing amyloid plaque burden and Alzheimer’s disease severity.
Reasons to Purchase the Report
- Current and future market outlook for Alzheimer's disease diagnostics and therapeutics in developed and emerging markets
- Analyzing various perspectives on the market with the help of Porter’s five forces analysis
- The segment that is expected to dominate the market
- The regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, market shares, and strategies employed by the major market players
- Three-month analyst support, along with the Market Estimate sheet in Excel.
This report can be customized to meet your requirements..
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1.1 Investment on Biomarkers for Drug Development
6.1.2 Increasing Pipeline Drug Development
6.1.3 Increasing Incidence and Prevalence of Alzheimer's disease
6.1.4 Increasing Sophisticated Diagnostics for Early Detection and Precise Drug Development
6.1.5 Emerging Novel Diagnostic Techniques
6.2 Market Restraints
6.2.1 Challenging Nature of the Early Diagnosis of the Indication
6.2.2 Decrease in the Market due to Failures of the Late-stage Drugs
6.2.3 Lack of Surrogate Markers for Drug Discovery and Drug Development
6.2.4 Insufficient Research Funding and Lengthy Uncertain Processes
6.4 Key Challenges
7. Market Segmentation
7.1 Segmentation - by Therapeutics
7.1.1 Cholinesterase Inhibitors
7.1.2 NMDA Receptor Antagonists
7.2 Segmentation - by Diagnostics
7.2.1 Brain Imaging
7.2.2 CSF Test for AD
7.3 Segmentation - by Geography
7.3.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 Australia & New Zealand
22.214.171.124 South Korea
126.96.36.199 Rest of Asia-Pacific
7.3.4 Middle East & Africa
188.8.131.52 South Africa
184.108.40.206 Rest of the Middle East & Africa
7.3.5 South America
220.127.116.11 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Product Launches
9. Key Players
9.1 F. Hoffmann-La Roche
9.3 Merck & Co.
9.4 Pfizer Inc
9.5 Eisai Co. Ltd
9.6 Biogen Inc
9.7 Johnson & Johnson
9.8 Eli Lily & Co
9.9 Amarantus Bioscience Holdings
9.10 DiaGenic ASA
9.11 Navidea Biopharmaceuticals Holdings Inc.
9.12 GE Healthcare
10. Future of the Market